Abstract #4203
Pharmacological MRI with T1 Contrast Agents
Richard Baheza 1 , Nellie Byun 2 , Adam Stark 3 , and John C. Gore 3,4
1
RADIOLOGY AND RADIOLOGICAL SCIENCES,
Vanderbilt University Medical Center, NASHVILLE, TN,
United States,
2
PHARMACOLOGY,
Vanderbilt University Medical Center, NASHVILLE, TN,
United States,
3
VANDERBILT
UNIVERSITY INSTITUTE OF IMAGING SCIENCE, Nashville, TN,
United States,
4
BIOMEDICAL
ENGINEERING, Vanderbilt University, Nashville, TN,
United States
We performed whole brain pharmacological MRI (phMRI) at
9.4T with the FDA approved T1 contrast agent Magnevist
using an optimized 3D acquisition sequence to detect
amphetamine-induced brain activity in rats. Increasing
the psychostimulant dose from 2.0 to 4.0 mg/kg elevated
the acquired signal increases from 1.870.55% to
4.710.33% in the caudate-putamen, demonstrating that
the method is sensitive to drug concentration. These
data validate the utility of using a T1 shortening agent
with 3D acquisition for phMRI. This method has
translational potential to clinical drug studies using
FDA-approved contrast agents.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
